The FDA has granted 510(k) clearance to Olympus' Narrow Band Imaging technology designed for improved visualization of tumor boundaries in non-muscle-invasive bladder cancer.
The FDA found that the Olympus technology visualized NMIBS lesions in 17 percent more patient when compared with white light, 24 percent additional tumor and 28 percent additional carcinoma in situ.
The new technology can be used in both the office and operating room.